Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma

about

Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma

Item

http://www.wikidata.org/entity/Q57132855

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Long-term outcomes of a phase ...... ients with metastatic melanoma

@en

Long-term outcomes of a phase ...... ients with metastatic melanoma

@nl

type

Item

label

Long-term outcomes of a phase ...... ients with metastatic melanoma

@en

Long-term outcomes of a phase ...... ients with metastatic melanoma

@nl

prefLabel

Long-term outcomes of a phase ...... ients with metastatic melanoma

@en

Long-term outcomes of a phase ...... ients with metastatic melanoma

@nl

P1476

Long-term outcomes of a phase ...... ients with metastatic melanoma

@en

P2093

Alex C Huang

http://www.w3.org/2001/XMLSchema#string

Brendan Sullivan

http://www.w3.org/2001/XMLSchema#string

David L Bajor

http://www.w3.org/2001/XMLSchema#string

Drew A Torigian

http://www.w3.org/2001/XMLSchema#string

E John Wherry

http://www.w3.org/2001/XMLSchema#string

Erietta Stelekati

http://www.w3.org/2001/XMLSchema#string

Fang Chen

http://www.w3.org/2001/XMLSchema#string

J Joseph Melenhorst

http://www.w3.org/2001/XMLSchema#string

Lee P Richman

http://www.w3.org/2001/XMLSchema#string

Lynn M Schuchter

http://www.w3.org/2001/XMLSchema#string

P2860

The future of immune checkpoint therapy

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.

Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma.

Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors.

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.

P304

e1468956

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/2162402X.2018.1468956

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30288340

http://www.w3.org/2001/XMLSchema#string

P921

immunology

P932

6169575

http://www.w3.org/2001/XMLSchema#string